Article
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2013
Nathanson Katherine L, Martin Anne-Marie, Wubbenhorst Bradley, Greshock Joel, Letrero Richard, D'Andrea Kurt, O'Day Steven, Infante Jeffrey R, Falchook Gerald S, Arkenau Hendrik-Tobias, Millward Michael, Brown Michael P, Pavlick Anna, Davies Michael A, Ma Bo, Gagnon Robert, Curtis Martin, Lebowitz Peter F, Kefford Richard, Long Georgina V
Abstract excerpt
PURPOSE: Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently showed improved progression-free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. This study examined potential genetic markers associated with response and PFS in the phase I stud...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.